SCHEMBL3533703

SCHEMBL3533703

CC1CCN(c2cc(C3CCN(C(=O)OC(C)(C)C)CC3)ccc2N)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.47
GPR119 Q8TDV5 10/20 0.47
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
THRB P10828 1/20 0.46
PDE4B Q07343 1/20 0.46
CSF1R P07333 1/20 0.44
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
NR4A1 P22736 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22955087 0.86 GPR119 (0.46) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL3541924 0.85 CSF1R (0.57) KDM4EMAPTPDE4BCSF1RNPC1
SCHEMBL27691389 0.85 GAA (0.51) KDM4EMAPTCSF1RNPC1ALDH1A1
SCHEMBL15157112 0.85 NAMPT (0.54) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL30778326 0.85 NAMPT (0.54) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL31000463 0.83 GPR119 (0.53) GPR119KDM4EMAPTLMNANPC1
SCHEMBL3541321 0.83 GPR119 (0.53) GPR119KDM4EMAPTLMNANPC1
SCHEMBL24793972 0.82 NAMPT (0.52) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL12479918 0.82 NAMPT (0.52) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL15862956 0.81 NAMPT (0.51) NAMPTGPR119KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES NAMPT 2462/4885GPR119 944/4885KDM4E 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.